Table 1

Baseline patient characteristics

Patients (n)23
Age (years)69.7±8.3
Female (%)34.8
Systolic BP (mm Hg)107.5±25.9
Diastolic BP (mm Hg)69.8±18.2
Heart rate (beats per minute)83.6±20.1
SPO2 (%)86.4±11.3
Blood biochemistry
  CK (peak, u/L)2011.9±2418.3
 CKMB (peak, u/L)168.1±199.3
 RBC (×109/L)4.1±0.6
 PLT (×109/L)180.7±58.7
 Creatine (µmol/L)88.7±24.9
Death (%)73.9
Early rupture (%)52.2
Late rupture (%)34.8
Ultrasonic cardiogram
 LVEDD (mm)54.3±5.2
 LVESD (mm)39.3±6.3
 EF (%)52.4±9.6
Hypertension (%)52.2
Diabetes (%)17.4
Cerebral infarction (%)17.4
CKD (%)0.0
COPD (%)4.2
STEMI18 (78.3%)
  Inferior posterior3
  High lateral3
  Inferior and right ventricle3
NSTEMI5 (21.7%)
Mean time to revascularization (hours)50.5
Patency rate of IRA (%)43.5
Surgery3 (13.0%)
IABP (%)8.3
Aspirin (%)87.5
Clopidogrel (%)82.6
Ticagrelor (%)4.3
β-blocker (%)60.9
ACEI/ARB (%)52.2
CCB (%)4.3
Statin (%)95.7
  • Data are mean±SD and n (%).

  • ACEI/ARB, ACE inhibitors/angiotensin II receptor blockers; BP, blood pressure; CCB, calcium channel blocker; CK, creatine kinase; CKD, chronic kidney disease; CKMB, creatine kinase isoenzyme-B; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; IAPB, intra-aortic balloon pump; IRA, infarct-related artery; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; NSTEMI, non-ST segment elevated myocardial infarction; PLT, platelets; RBC, red blood cell; SPO2, oxyhemoglobin saturation by pulse oximetry; STEMI, ST segment elevated myocardial infarction.